39050-08-3

Basic information

• Product Name: N-(2-{(2Z)-2-[(4-bromophenyl)hydrazono]-2H-imidazol-4-yl}ethyl)acetamide
• CAS NO: 39050-08-3
• Molecular Formula: C₁₃H₁₄BrN₅O
• Molecular Weight: 336.1872
• Mol File: 39050-08-3.mol

Chemical Properties

• Density: 1.54g/cm³
• Refractive Index: 1.666
• CAS DataBase Reference: N-(2-{(2Z)-2-[(4-bromophenyl)hydrazono]-2H-imidazol-4-yl}ethyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-{(2Z)-2-[(4-bromophenyl)hydrazono]-2H-imidazol-4-yl}ethyl)acetamide(39050-08-3)
• EPA Substance Registry System: N-(2-{(2Z)-2-[(4-bromophenyl)hydrazono]-2H-imidazol-4-yl}ethyl)acetamide(39050-08-3)

Safety Data

• Hazardous Substances Data: 39050-08-3(Hazardous Substances Data)

Upstream product

• 2028-85-5 (4-bromophenyl)diazonium chloride 
• 673-49-4 Nω-acetylhistamine 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 39050-13-0 2-aminohistamine 

Relevant articles and documents

AMINO-HETEROARYL-CONTAINING PROKINETICIN 1 RECEPTOR ANTAGONISTS

The present invention relates to certain novel compounds of Formula (I): and methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.

Design, synthesis, and biological evaluation of pyrazinones containing novel P1 needles as inhibitors of TF/VIIa

Herein is described the design, synthesis, and enzymatic activity of a series of substituted pyrazinones as inhibitors of the TF/VIIa complex. These inhibitors were designed to explore replacement and variation of the P1 amidine described previously [J. Med. Chem. 2003, 46, 4050]. The P1 needle replacements were selected based upon their reduced basicity compared to the parent phenyl amidine (pKa ～ 12). A contributing factor towards the oral bioavailability of a compound is the ionization state of the compound in the intestinal tract. The desired outcome of the study was to identify an orally bioavailable TF-VIIa inhibitor.